FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3196789898> ?p ?o ?g. }

• W3196789898 endingPage "1347" @default.
• W3196789898 startingPage "1347" @default.
• W3196789898 abstract "Acute respiratory distress syndrome (ARDS), a catastrophic illness of multifactorial etiology, involves a rapid upsurge in inflammatory cytokines that leads to hypoxemic respiratory failure. Dexamethasone, a synthetic corticosteroid, mitigates the glucocorticoid-receptor-mediated inflammation and accelerates tissue homeostasis towards disease resolution. To minimize non-target organ side effects arising from frequent and chronic use of dexamethasone, we designed biodegradable, lung-targeted microspheres with sustained release profiles. Dexamethasone-loaded lipopolymeric microspheres of PLGA (Poly Lactic-co-Glycolic Acid) and DPPC (Dipalmitoylphosphatidylcholine) stabilized with vitamin E TPGS (D-α-tocopheryl polyethylene glycol succinate) were prepared by a single emulsion technique that had a mean diameter of 8.83 ± 0.32 μm and were spherical in shape as revealed from electron microscopy imaging. Pharmacokinetic and biodistribution patterns studied in the lungs, liver, and spleen of Wistar rats showed high selectivity and targeting efficiency for the lung tissue (re 13.98). As a proof-of-concept, in vivo efficacy of the microspheres was tested in the lipopolysaccharide-induced ARDS model in rats. Inflammation markers such as IL-1β, IL-6, and TNF-α, quantified in the bronchoalveolar lavage fluid indicated major improvement in rats treated with dexamethasone microspheres by intravenous route. Additionally, the microspheres substantially inhibited the protein infiltration, neutrophil accumulation and lipid peroxidation in the lungs of ARDS bearing rats, suggesting a reduction in oxidative stress. Histopathology showed decreased damage to the pulmonary tissue upon treatment with the dexamethasone-loaded microspheres. The multipronged formulation technology approach can thus serve as a potential treatment modality for reducing lung inflammation in ARDS. An improved therapeutic profile would help to reduce the dose, dosing frequency and, eventually, the toxicity." @default.
• W3196789898 created "2021-09-13" @default.
• W3196789898 creator A5001934184 @default.
• W3196789898 creator A5019618589 @default.
• W3196789898 creator A5020881206 @default.
• W3196789898 creator A5026817645 @default.
• W3196789898 creator A5040297048 @default.
• W3196789898 creator A5071895356 @default.
• W3196789898 creator A5074675838 @default.
• W3196789898 creator A5078206961 @default.
• W3196789898 date "2021-08-27" @default.
• W3196789898 modified "2023-10-16" @default.
• W3196789898 title "Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS" @default.
• W3196789898 cites W1964326818 @default.
• W3196789898 cites W1981251269 @default.
• W3196789898 cites W1990425995 @default.
• W3196789898 cites W2002051062 @default.
• W3196789898 cites W2005120206 @default.
• W3196789898 cites W2009845520 @default.
• W3196789898 cites W2029525090 @default.
• W3196789898 cites W2033999645 @default.
• W3196789898 cites W2051931515 @default.
• W3196789898 cites W2066435094 @default.
• W3196789898 cites W2083976666 @default.
• W3196789898 cites W2123624166 @default.
• W3196789898 cites W2131135326 @default.
• W3196789898 cites W2139878458 @default.
• W3196789898 cites W2159379486 @default.
• W3196789898 cites W2486827556 @default.
• W3196789898 cites W2548097234 @default.
• W3196789898 cites W2606085194 @default.
• W3196789898 cites W2765228582 @default.
• W3196789898 cites W2784261849 @default.
• W3196789898 cites W2793442065 @default.
• W3196789898 cites W2886053151 @default.
• W3196789898 cites W2891987403 @default.
• W3196789898 cites W2895456059 @default.
• W3196789898 cites W2896249550 @default.
• W3196789898 cites W2942388045 @default.
• W3196789898 cites W2944419582 @default.
• W3196789898 cites W2944436875 @default.
• W3196789898 cites W2981218165 @default.
• W3196789898 cites W2996109219 @default.
• W3196789898 cites W2997201270 @default.
• W3196789898 cites W3001854072 @default.
• W3196789898 cites W3004626187 @default.
• W3196789898 cites W3017743621 @default.
• W3196789898 cites W3022205379 @default.
• W3196789898 cites W3036026378 @default.
• W3196789898 cites W3044219705 @default.
• W3196789898 cites W3078010481 @default.
• W3196789898 cites W3088833607 @default.
• W3196789898 cites W3103306322 @default.
• W3196789898 cites W3104201883 @default.
• W3196789898 cites W3112976334 @default.
• W3196789898 cites W3156774485 @default.
• W3196789898 cites W3157841475 @default.
• W3196789898 cites W3169375391 @default.
• W3196789898 cites W3186274567 @default.
• W3196789898 cites W4321320006 @default.
• W3196789898 cites W63334620 @default.
• W3196789898 cites W2085695343 @default.
• W3196789898 doi "https://doi.org/10.3390/pharmaceutics13091347" @default.
• W3196789898 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8471313" @default.
• W3196789898 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34575422" @default.
• W3196789898 hasPublicationYear "2021" @default.
• W3196789898 type Work @default.
• W3196789898 sameAs 3196789898 @default.
• W3196789898 citedByCount "9" @default.
• W3196789898 countsByYear W31967898982021 @default.
• W3196789898 countsByYear W31967898982022 @default.
• W3196789898 countsByYear W31967898982023 @default.
• W3196789898 crossrefType "journal-article" @default.
• W3196789898 hasAuthorship W3196789898A5001934184 @default.
• W3196789898 hasAuthorship W3196789898A5019618589 @default.
• W3196789898 hasAuthorship W3196789898A5020881206 @default.
• W3196789898 hasAuthorship W3196789898A5026817645 @default.
• W3196789898 hasAuthorship W3196789898A5040297048 @default.
• W3196789898 hasAuthorship W3196789898A5071895356 @default.
• W3196789898 hasAuthorship W3196789898A5074675838 @default.
• W3196789898 hasAuthorship W3196789898A5078206961 @default.
• W3196789898 hasBestOaLocation W31967898981 @default.
• W3196789898 hasConcept C126322002 @default.
• W3196789898 hasConcept C142724271 @default.
• W3196789898 hasConcept C185592680 @default.
• W3196789898 hasConcept C2776348555 @default.
• W3196789898 hasConcept C2776914184 @default.
• W3196789898 hasConcept C2777714996 @default.
• W3196789898 hasConcept C2777961210 @default.
• W3196789898 hasConcept C2780401358 @default.
• W3196789898 hasConcept C71924100 @default.
• W3196789898 hasConcept C98274493 @default.
• W3196789898 hasConceptScore W3196789898C126322002 @default.
• W3196789898 hasConceptScore W3196789898C142724271 @default.
• W3196789898 hasConceptScore W3196789898C185592680 @default.
• W3196789898 hasConceptScore W3196789898C2776348555 @default.
• W3196789898 hasConceptScore W3196789898C2776914184 @default.
• W3196789898 hasConceptScore W3196789898C2777714996 @default.

• next